VPR Brands Announces Favorable Settlement of Second Patent Infringement Case
January 06, 2022 08:00 ET
|
VPR Brands LP
FORT LAUDERDALE, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- VPR Brands, LP (OTC: VPRB): VPR Brands is a market leader and pioneer in electronic cigarettes and vaporizers for nicotine, cannabis and...
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
January 04, 2022 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
22nd Century Ready to Provide Full Commercial Support to New Zealand’s Plan to Reduce Nicotine Content of All Cigarettes
December 10, 2021 09:20 ET
|
22nd Century Group, Inc
New Zealand Ministry of Health announced aggressive measures to reduce smoking, including a reduced nicotine mandate by 2025 22nd Century fully engaged and ready to support New Zealand’s government...
Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation
November 23, 2021 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
November 22, 2021 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development
November 09, 2021 16:05 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leader in Emerging Psychedelic-Assisted Psychotherapy Industry
November 04, 2021 08:30 ET
|
Mydecine Innovations Group Inc.
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announces the availability of a broadcast titled, “Breaking the Habit:...
Achieve Life Sciences Announces Participation in November Investor Conferences
November 04, 2021 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessation
November 02, 2021 08:30 ET
|
Achieve Life Sciences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Part of Psychedelic Medicine Research Renaissance
November 02, 2021 08:30 ET
|
Mydecine Innovations Group Inc.
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) today announces its placement in an editorial published by...